The Centers for Medicare and Medicaid Services announced a rule cutting off federal Medicaid and CHIP dollars for sex-change hormones, puberty blockers, and surgeries on children, a move officials say follows the science and protects kids from irreversible harm.
CMS Administrator Dr. Mehmet Oz and Health and Human Services Secretary Robert F. Kennedy Jr. confirmed the policy Tuesday, telling Fox News Digital that American taxpayers will no longer foot the bill for what the administration calls unproven medical interventions on minors. The rule covers cross-sex hormones, puberty blockers, and surgical operations funded through both Medicaid and the Children's Health Insurance Program.
Children currently receiving hormone treatments will not lose coverage overnight. The rule includes a six-month phase-out period from the date it takes effect, giving families and providers time to adjust. Mental health treatments for gender dysphoria and other conditions remain covered under both programs.
Oz framed the announcement as a direct extension of the administration's broader stance on children's health. In a statement, the CMS administrator said the rule is:
"consistent with [the Trump administration's] commitment to protect children from experimental and life-altering sex-rejecting procedures that carry serious long-term health risks and lack sufficiently reliable evidence of clinical benefit."
He went further in a second statement, connecting the funding cut to both fiscal responsibility and medical caution.
"Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."
Kennedy echoed that position. The HHS secretary pointed to the potential for permanent physical damage as the core justification for pulling federal money.
"Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve."
CMS and HHS stated that gender transition procedures on minors can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects. That language came directly from the agencies in conjunction with the rule announcement.
The administration did not rely on political arguments alone. HHS reviewed national and international research on gender transition procedures in minors before CMS moved forward. That review, officials said, identified significant evidence gaps and documented serious safety concerns.
One cornerstone of the decision was the 2024 Cass Review, an independent clinical assessment conducted in the United Kingdom by Dr. Hilary Cass. The review concluded that research on cross-sex hormones and puberty blockers was "limited and not definitive." It also found that the medical interventions themselves had developed significantly faster than the evidence proving they were safe. CMS pointed to the Cass Review as one of the central pieces of research informing the new rule.
That finding, that the treatments outpaced the proof, is exactly the kind of gap that should give any regulator pause. When the best independent review available says the science has not caught up to the medicine, continuing to spend taxpayer dollars on those procedures is a policy choice, not a medical one.
HHS Press Secretary Emily Hilliard reinforced the administration's position in a statement to Fox News Digital.
"The Trump Administration is drawing a clear line: America's children will not be subjected to life-altering interventions on the taxpayer's dime without reliable evidence of safety and clinical benefit."
Hilliard added that under Kennedy's leadership, federal health care dollars will support evidence-based care that "protects children and puts their long-term health first." She said American taxpayers "should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible."
The Medicaid funding cut is only part of the administration's broader strategy. The Washington Examiner reported that CMS spent $30 million in Medicaid payments in 2023 for gender transition medicine for minors, with a projected $250 million over the next decade. But the proposed rules go further than simply ending reimbursement for specific procedures. Under the broader CMS proposal, hospitals that perform gender transition procedures on minors under 18 could lose all Medicare and Medicaid funding, not just funding related to gender procedures.
That distinction matters enormously. Nearly every hospital in the country depends on Medicare and Medicaid revenue. Losing access to those programs would be financially devastating, which is precisely the point. Kennedy, in remarks reported by the Examiner, did not hold back about the industry he believes has grown around these procedures.
Meanwhile, some state-level Democrats have moved in the opposite direction, pushing to expand taxpayer-funded gender transition coverage even as the federal government pulls back.
Breitbart reported that a senior administration official described the rule as one that would "effectively end sex-trait modifications for minors nationally" if finalized. The proposed rule, formally titled "Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex Trait Modifications for Children," represents what the official called the strongest federal lever available. The FBI, DOJ, and FTC are also conducting ongoing investigations into hospitals and doctors providing these procedures to minors.
Nearly two dozen hospitals had already restricted sex-change drugs and surgeries before the rule was even finalized, responding to the direction of the administration's enforcement posture.
The hospital retreat is not limited to those two dozen early movers. The New York Post reported that more than 40 hospitals nationwide have ended transgender youth treatment programs since January 2025. One high-profile case involved NYU Langone, which shut down its program only to face legal threats from New York Attorney General Letitia James. Deputy Attorney General Todd Blanche sent James a letter warning that the DOJ "will take all necessary actions to defend" NYU Langone if she pursued legal action against the hospital for ending the treatments.
Blanche's position was blunt: anti-discrimination laws cannot be used to compel a hospital to perform gender-related procedures on minors. Oz weighed in on the NYU Langone standoff as well, saying simply, "Our children are not guinea pigs." James blew past her own self-imposed deadline for NYU Langone to reinstate the treatments, and the DOJ's intervention effectively put her on notice.
That standoff captures the broader tension. State-level officials in progressive jurisdictions have tried to use legal pressure to keep these programs running, even as the federal government and a growing body of international research move in the other direction. In Colorado, the state's highest court ordered a children's hospital to resume gender transition treatments for minors, setting up a direct collision between state mandates and federal funding rules.
The regulatory filing itself, designated CMS-2451 and titled "Medicaid Program; Prohibition on Federal Medicaid Funding for Sex Trait Modification Procedures Furnished to Children and Youth", was submitted to the White House's Office of Information and Regulatory Affairs for review, National Review confirmed. The full text has not yet been made public while it remains under regulatory review.
Legal challenges are expected. The Washington Examiner noted that the proposed rules face a 60-day public comment period, and opponents will almost certainly mount court challenges. But the administration's approach is designed to survive those fights by grounding the rule in the same evidentiary standard that the Cass Review applied: if the science does not support the treatment, the federal government has no obligation to pay for it.
Kennedy signed a declaration finding that gender transition procedures for minors "do not meet professionally recognized standards of care," based on a peer-reviewed HHS report. That declaration, combined with the CMS rule and the DOJ's willingness to intervene on behalf of hospitals that stop offering the procedures, creates a layered enforcement framework that does not depend on any single regulation surviving a legal challenge.
Some Democratic lawmakers continue to push back. In Texas, a Senate hopeful doubled down on support for transgender care, calling Republican opposition a "divide-and-conquer" strategy. And in Colorado, one state Democrat sponsored legislation requiring insurers to cover gender transitions for minors, the exact opposite of the federal trajectory.
Several open questions remain. The rule's precise effective date has not been announced, and neither CMS nor HHS has disclosed how many minors currently receive Medicaid- or CHIP-funded gender transition treatments. The boundary between prohibited procedures and the mental health treatments that will continue to be covered has not been publicly defined in detail.
But the direction is unmistakable. The federal government has decided that taxpayer dollars will no longer fund medical procedures on children that the best available evidence cannot prove are safe, and it is willing to put every hospital's Medicare funding on the line to enforce that decision.
When the science says "we don't know yet" and the procedures are irreversible, protecting children is not a culture-war position. It is common sense.
